Autophagy Inhibition to Augment mTOR Inhibition: a Phase I/II Trial of Everolimus and Hydroxychloroquine in Patients with Previously Treated Renal Cell Carcinoma.

Naomi B HaasLeonard J ApplemanMark SteinMaryann RedlingerMelissa WilksXiaowei XuAngelique OnoratiAnusha KalavacharlaTaehyong KimChao Jie ZhenSabah KadriJeremy P SegalPhyllis A GimottyLisa E DavisRavi K Amaravadi

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)

Combined hydroxychloroquine 600 mg twice daily with 10 mg daily everolimus was tolerable. The primary endpoint of >40% 6-month PFS rate was met. Hydroxychloroquine is a tolerable autophagy inhibitor in future RCC or other trials.

Keyphrases

renal cell carcinoma
cell death
endoplasmic reticulum stress
signaling pathway
physical activity
oxidative stress
study protocol
cell proliferation
phase iii
tyrosine kinase
phase ii
open label